Graf Akcie CHRS (Coherus Biosciences Inc). Diskuze k akciím CHRS. Aktuální informace CHRS.

Základní informace o společnosti Coherus Biosciences Inc (Akcie CHRS)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 1.34B
Hodnota podniku (EV) N/A
Tržby 394.647M
EBITDA N/A
Zisk -165.21
Růst v tržbách Q/Q -35.40 %
Růst v tržbách Y/Y -19.03 %
P/E (Cena vůči ziskům) 0.00
Forward P/E -0.31
EV/Sales 2.97
EV/EBITDA N/A
EV/EBIT 7.11
PEG 0.30
Price/Sales 3.41
P/FCF 17.22
Price/Book 4.78
Účetní hodnota na akcii 3.55
Hotovost na akcii 6.85
FCF vůči ceně 5.81 %
Počet zaměstnanců 317
Tržba na zaměstnance 1245000
Profit margin 27.79 %
Operating margin -35.83 %
Gross margin 92.08 %
EBIT margin -35.79 %
EBITDA margin 22.72 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst -151.43 %
EPS - Očekávaný růst příští rok -175.76 %
Return on assets -21.47 %
Return on equity -80.53 %
ROIC 25.09 %
ROCE -31.22 %
Dluhy/Equity 2.00
Čistý dluh/EBITDA -1.12
Current ratio 2.30
Quick Ratio 1.96
Volatilita 4.02
Beta 0.97
RSI 52.59
Cílová cena analytiků 30
Známka akcie (dle analytiků) N/A
Insider ownership N/A %
Institutional ownership N/A %
Počet akcií 76.48M
Procento shortovaných akcií 17.01 %
Short ratio 16.59 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2014
Země United States

Finanční výsledky akcie CHRS

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$356.071-$1.556$190.106$30.041$31.106
Cost Of Goods Sold$17.078-----
Gross Profit$338.993-$1.556$190.106$30.041$31.106
Research And Development Expenses$94.188$110.239$162.389$254.44$213.062$78.224
SG&A Expenses$137.037$94.177$71.303$51.597$36.046$17.564
Other Operating Income Or Expenses------
Operating Expenses$248.303$204.416$233.692$306.037$249.108$95.788
Operating Income$107.768$-204.416$-232.136$-115.931$-219.067$-64.682
Total Non-Operating Income/Expense$-14.993$-4.993$-6.15$-11.857$-4.871$-22.495
Pre-Tax Income$92.775$-209.409$-238.286$-127.788$-223.938$-87.177
Income Taxes$2.942-----
Income After Taxes$89.833$-209.409$-238.286$-127.788$-223.938$-87.177
Other Income------
Income From Continuous Operations$89.833$-209.409$-238.286$-127.788$-223.938$-87.177
Income From Discontinued Operations------
Net Income$89.833$-209.339$-238.17$-127.337$-223.26$-87.133
EBITDA$111.027$-201.181$-228.738$-112.935$-217.198$-64.008
EBIT$107.768$-204.416$-232.136$-115.931$-219.067$-64.682
Basic Shares Outstanding70655342378
Shares Outstanding73655342378
Basic EPS$1.29$-3.22$-4.48$-3.04$-6.01$-10.64
EPS - Earnings Per Share$1.23$-3.22$-4.48$-3.04$-6.01$-10.64
# 2020 2019 2018 2017 2016 2015
Current Ratio2.98352.53855.12332.86441.86183.4594
Long-term Debt / Capital0.6291.59830.76890.8382--
Debt/Equity Ratio1.6955-2.67143.32765.1801--
Gross Margin95.2038-100100100100
Operating Margin30.2659--14918.77-60.9823-729.2267-207.9406
EBIT Margin30.2659--14918.77-60.9823-729.2267-207.9406
EBITDA Margin31.1811--14700.39-59.4063-723.0052-205.7738
Pre-Tax Profit Margin26.0552--15314.01-67.2193-745.4412-280.2578
Net Profit Margin25.229--15306.55-66.9821-743.1843-280.1164
Asset Turnover0.8707-0.00961.06510.14140.1661
Inventory Turnover Ratio1.7414-----
Receiveable Turnover2.5077--102.262519.257112.8697
Days Sales In Receivables145.5527--3.569218.954128.3613
ROE - Return On Equity85.3812542.6374-780.3707-660.26723231.895-130.5885
Return On Tangible Equity88.374496.7714-883.4573-809.24562134.369-137.9514
ROA - Return On Assets21.968-210.5311-146.5374-71.5959-105.4402-46.5637
ROI - Return On Investment31.676-324.66-180.3243-106.83723231.895-130.5885
Book Value Per Share1.4952-0.5650.51030.4225-0.17762.0072
Operating Cash Flow Per Share2.83631.32062.2561-3.11650.0135-7.5514
Free Cash Flow Per Share2.82361.39442.3255-3.10590.1955-7.7874